Alzamend Neuro, Inc. — Director's Dealing 2021

Aug 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-08-04

Reporting Person: AULT MILTON C III (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-04	Common Stock	P	500	$4.3009	Acquired	6682388	Indirect
2021-08-05	Common Stock	P	1000	$4.21	Acquired	6683388	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-04	Call Option (right to buy)	$5.00	P	10	Acquired	2022-02-18	Common Stock (1000)	Indirect
2021-08-05	Call Option (right to buy)	$10.00	P	60	Acquired	2022-02-18	Common Stock (6000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15000000	Indirect
Common Stock	10000000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Call Option (right to buy)	$10.00	2021-08-20	Common Stock (50000)	500	Indirect
Call Option (right to buy)	$7.50	2022-02-18	Common Stock (3000)	30	Indirect
Call Option (right to buy)	$2.50	2022-02-18	Common Stock (1000)	10	Indirect

Footnotes

F1: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.3009. The range of purchase prices on the transaction date was $4.2482 to $4.336 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.

F2: Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.

F3: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.21. The range of purchase prices on the transaction date was $4.20 to $4.22 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.

F4: Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

F5: Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

F6: The security listed is an exchange-traded option contract. Exchange-traded options are immediately exercisable and remain exercisable until expiration.